Navigation Links
CardioDx Completes Validation Study of First-Of-Its-Kind Genomic Test for Coronary Artery Disease
Date:8/25/2009

PALO ALTO, Calif., Aug. 25 /PRNewswire/ -- CardioDx, a cardiovascular genomic diagnostics company, announced today that the company has successfully completed its multicenter validation study for Corus(TM) CAD, the first and only gene expression test to quantify the likelihood of obstructive(1) coronary artery disease (CAD) in patients with stable chest pain. The company expects to present results of the study by the end of 2009, and will publish the results in 2010.

Following completion of the validation study, CardioDx has made Corus CAD available in nine states initially, with broader availability expected in 2010. The test is now available in Kentucky, Maryland, Illinois, Washington, Wisconsin, Minnesota, North Carolina, Texas and Arizona. Patient samples are processed in Palo Alto at CardioDx's CLIA-certified laboratory.

"Completing the validation study for Corus CAD marks a major milestone for CardioDx," said David Levison, chief executive officer of CardioDx. "Our focus now turns to further developing the clinical and economic evidence needed to increase patient access to the unique benefits of Corus CAD."

Currently, the presence of obstructive CAD in patients with stable chest pain is most often evaluated through functional and/or anatomical assessment of the heart and its vessels, including stress echocardiography, myocardial perfusion imaging, and computed tomography angiography. However, despite advances in imaging technology, these techniques can be subjective and challenging for cardiologists, because of variation in presenting symptoms and each patient's unique disease characteristics. Corus CAD provides unique genomic information about an individual's disease processes at the molecular and cellular levels. When this information is combined with standard clinical assessments, physicians obtain a more complete picture of their patient's disease and can bett
'/>"/>

SOURCE CardioDx
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX ), ... serving the pharmaceutical, biotechnology, and medical device industries, with ... the United States , today announced the ... Tel Aviv area of Israel.  ... of integrated R&D services to local customers. It will ...
(Date:10/30/2014)... , Oct. 30, 2014  The number of ... is growing steadily, thanks to drug store ... a result of the economic downturn, retail clinic growth ... year of opportunities, as the number of retail clinics ... report, Retail Clinics Market Overview and 2014 Consumer ...
(Date:10/30/2014)...   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade hypothermic storage and ... products for cells and tissues, today announced today ... be released on Thursday, November 6, 2014, and that ... webcast at 1:30 p.m. PST that afternoon. Management will ...
Breaking Medicine Technology:WuXi AppTec Launches Representative Office in Israel, Forms Strategic Collaboration with Pontifax 2Report: Drugstore Chains Drive Retail Clinic Growth 2Report: Drugstore Chains Drive Retail Clinic Growth 3BioLife Solutions to Report Financial Results for Third Quarter 2014 and Provide Business Update on November 6, 2014 2
... Inc . announced today that David A. Weber, Ph.D. , ... Board of Directors. Jay Lichter, Ph.D., managing director of Avalon Ventures, ... actively support the company as a member of the Board of ... to the Otonomy team, as his extensive experience in the development ...
... 2010 Amicus Therapeutics (Nasdaq: FOLD ), ... diseases, today announced that it has been awarded a ... Parkinson,s Research (MJFF) for the development of a novel, ...  The $500,000 award will be distributed over a period ...
Cached Medicine Technology:Otonomy Appoints David A. Weber, Ph.D., Chief Executive Officer 2Otonomy Appoints David A. Weber, Ph.D., Chief Executive Officer 3Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 2Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 3Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 4Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 5
(Date:10/30/2014)... 30, 2014 Home Care Assistance – ... of non-medical, in-home senior care, is weighing in on ... health. , The study, performed by the University of ... and 78 over a week-long period and observed how ... physical activity. By examining the structural soundness of the ...
(Date:10/30/2014)... 2014 Global prebiotics market is expected ... a new study by Grand View Research, Inc. Positive ... sugar and fat free products owing to increased concerns ... prebiotics over the forecast period. , View full report ... & beverage was the largest application segment with market ...
(Date:10/30/2014)... The human brain is often overlooked ... to help maintain better mental health, according to Dr. ... Lose Your Memory in 100 Ways’ for just that ... conflicting attitudes to help keep the reader constantly thinking. ... must decipher the hidden logic within. , “If you ...
(Date:10/30/2014)... Sound Telecom, a leader in the call center industry, ... time they wonder, “Should I use an answering service?” The ... through a series of yes or no questions that ultimately ... are many considerations and scenarios that come into play when ... . This decision infographic serves as a bit of a ...
(Date:10/30/2014)... HealthDay Reporter WEDNESDAY, Oct. ... chemical during pregnancy may have effects on genital development in ... baby boys born to moms with greater exposure to a ... -- the space between the genitals and anus. Anogenital distance ... of exposure to androgens ("male" hormones) during pregnancy. The ...
Breaking Medicine News(10 mins):Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 2Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 2Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 3Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 4Health News:Prebiotics Market Is Expected To Grow At A CAGR Of 9.3% From 2014 To 2020: Grand View Research, Inc. 5Health News:‘Dementia Express’ Offers Contradictory and Sometimes Reverse Thinking, All to Keep its Reader on Their Toes With an Active Mind. 2Health News:Sound Telecom Produces Decision Infographic to Aid Businesses 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 3
... ... set…GO! Summer kicks off each year with the City of Laguna ... year, the event is expected to bring out more than 6,000 runners, ... Day – Monday May 31. Registration is available online at www.lagunahillshalfmarathon.com ...
... , ... its place as one of the world,s leading medical hubs as it performs an ... and debilitating condition. , ... Singapore (PRWEB), May 6, 2010 -- Singapore,s oldest and largest tertiary acute hospital ...
... imaging (MRI) should be the imaging modality of choice for ... spread beyond the breast) as it is highly accurate and ... (shows no symptoms), according to a study to be presented ... Whole body MRI is a noninvasive medical test that ...
... Results from the SPIRIT IV clinical trial, which were ... scientific symposium, were published today in the New ... trial, a large-scale multi-center study of nearly 4,000 patients ... safety and efficacy in the treatment of de novo ...
... ... questions in the "By the Way, Doctor" feature. The newsletter,s May 2010 issue answers 13 ... Boston ... Letter offers answers to readers, serious, whimsical, and just plain curious questions ranging from ...
... discovered that the ovarian hormone progesterone plays a pivotal ... has important implications for breast cancer risk. ... (10.1038/nature09091; http://dx.doi.org/ ), are significant because reproductive history ... says principal investigator Rama Khokha, a molecular biologist at ...
Cached Medicine News:Health News:City of Laguna Hills Announces Memorial Day Half Marathon and 5K 2Health News:Singapore Performs Asia's First Combined Heart and Liver Transplant 2Health News:Singapore Performs Asia's First Combined Heart and Liver Transplant 3Health News:Singapore Performs Asia's First Combined Heart and Liver Transplant 4Health News:Singapore Performs Asia's First Combined Heart and Liver Transplant 5Health News:Whole body MRI is highly accurate in the early detection of breast cancer metastases 2Health News:Study finds everolimus-eluting stent safer, more effective than paclitaxel-eluting stent 2Health News:Harvard Health Letter Features Q&As from Harvard Doctors 2Health News:PMH cancer researchers link ovarian hormone to breast stem cells growth 2
Picofluor™ Fluorometer is a lightweight, inexpensive, handheld fluorometer, configured for the fluorescent probes commonly used for nucleic acid and protein quantitation....
Inquire...
The FluoroMax-3 is the entry level spectrofluorometer from Spex®, yet offers features not found in most of the top models of the competition....
... The BTF-111 miniature ... a user-con?gured spectrometer for ... nm. Con?gurable excitation light ... ?exibility of 2D ?uorescence ...
Medicine Products: